about
Differential diagnostics of pain in the course of trigeminal neuralgia and temporomandibular joint dysfunction.Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to dateSystemic IL-6 Effector Response in Mediating Systemic Bone Loss Following Inhalation of Organic DustAnhuienoside C Ameliorates Collagen-Induced Arthritis through Inhibition of MAPK and NF-κB Signaling Pathways.Level of inflammatory cytokines in rheumatoid arthritis patients: Correlation with 25-hydroxy vitamin D and reactive oxygen species.Cytokine-modulating strategies and newer cytokine targets for arthritis therapy.Smoking and rheumatoid arthritis.Hypomethylation of interleukin 6 correlates with renal involvement in systemic lupus erythematosus.The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.Crude triterpenoid saponins from Anemone flaccida (Di Wu) exert anti-arthritic effects on type II collagen-induced arthritis in rats.A Feedback Loop between Inflammation and Zn Uptake.Chemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys.IL-6 and IL-17A degradation by mast cells is mediated by a serglycin:serine protease axisSemaphorin 4D Contributes to Rheumatoid Arthritis by Inducing Inflammatory Cytokine Production: Pathogenic and Therapeutic Implications.Assessment of the -174G/C (rs1800795) and -572G/C (rs1800796) Interleukin 6 Gene Polymorphisms in Egyptian Patients with Rheumatoid Arthritis.Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs.Probing binding mechanism of interleukin-6 and olokizumab: in silico design of potential lead antibodies for autoimmune and inflammatory diseases.Sirukumab: a promising therapy for rheumatoid arthritis.Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dSuppression and resolution of autoimmune arthritis by rhesus θ-defensin-1, an immunomodulatory macrocyclic peptide.
P2860
Q27028022-703EE885-F05F-47BA-B684-8334454DA813Q28076558-62BD3BF1-4FF1-49C1-9232-F2E49BDA8DE8Q29048648-B0462B6E-963A-43DB-8078-295E65460904Q33729282-82E18061-0F03-47CE-A6EB-35C3070DED39Q33778590-B062FC86-982D-45BB-875F-F09A15F5E903Q34456715-814B13F3-5DE2-4CE2-A0B7-E1C7C9716A6BQ34834289-0F336F76-1663-469D-B9F1-91A0667E15F1Q35631910-9F2DDF1D-DD92-4C48-A7B9-A4D34471AEF5Q35764862-1CDEEC61-4224-4400-A049-02BCB8C04E89Q35888963-DCBAD270-4F48-413F-ACEC-892EF5D31AE7Q35914585-9BC2F552-EBD5-4F69-800E-C51F368C037FQ36579912-7442B6FF-539B-4FE0-8453-0E3BB83B20A5Q36621030-BB3B736E-EBA5-417D-928D-9B378089CE8DQ37275562-A9C5BA89-2AAE-4DBA-9E26-BBC1C156AB74Q37523537-D95E2ADA-973E-40C3-B350-DC26B30113DBQ38207142-75DF63CB-59FE-4F8F-B837-1F5A230751CDQ38382090-B0D82E72-6A10-4D97-A819-6A2580104375Q38856800-0D7947B9-11F6-46D8-9F8D-30C94DCA6283Q39176539-0B182743-FEA1-4459-8E3A-C282F5E664A9Q40772658-6EF809F7-F531-4E59-9495-1CE1D02A1B8BQ45589559-0C078952-53E0-49CC-A9C2-D0B2E2536C0A
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Interleukin 6 and rheumatoid arthritis
@en
Interleukin 6 and rheumatoid arthritis.
@nl
type
label
Interleukin 6 and rheumatoid arthritis
@en
Interleukin 6 and rheumatoid arthritis.
@nl
prefLabel
Interleukin 6 and rheumatoid arthritis
@en
Interleukin 6 and rheumatoid arthritis.
@nl
P2860
P921
P356
P1476
Interleukin 6 and rheumatoid arthritis
@en
P2093
Yuji Yoshida
P2860
P304
P356
10.1155/2014/698313
P407
P5008
P577
2014-01-12T00:00:00Z